Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kuruvilla, John  [Clear All Filters]
2023
Gong IY, Aminilari M, Landego I, Hueniken K, Zhou Q, Kuruvilla J, Hodgson DC. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials. Leuk Lymphoma. 2023:1-12.
Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, et al. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023:JCO2300570.
2022
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Dif. J Clin Oncol. 2022:JCO2200478.
Perales M-A, Kuruvilla J, Snider JThornton, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel A, Johnston P. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022.
2021
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LMaria, Goncalves I, de Oliveira JSR, Buccheri V, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021.
2019
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, et al. Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability. Biol Blood Marrow Transplant. 2019.
Tang C, Kuruvilla J. Optimal management of mantle cell lymphoma in the primary setting. Expert Rev Hematol. 2019.
2015
Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DDong Hwan. Mycophenolate based GVHD prophylaxis is not inferior to methotrexate in myeloablative related donor stem cell transplantation. Am J Hematol. 2015.
2014
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, C Kouroukis T, Rubinger M, Buckstein R, Imrie KR, Federico M, et al. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014.